Viking Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 85.9 million compared to USD 68.87 million a year ago. Basic loss per share from continuing operations was USD 0.91 compared to USD 0.9 a year ago.
Market Closed -
Other stock markets
|
After market 06:30:10 pm | |||
67.52 USD | +0.77% | 67.28 | -0.36% |
May. 17 | Raymond James Upgrades Viking Therapeutics to Strong Buy From Outperform | MT |
May. 17 | North American Morning Briefing : The "Everything -2- | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+262.79% | 7.44B | |
+9.58% | 115B | |
+12.41% | 107B | |
-3.52% | 21.6B | |
-12.38% | 22.31B | |
-6.91% | 19.19B | |
-3.35% | 18.23B | |
-38.57% | 17.62B | |
+7.51% | 14.26B | |
+35.67% | 12.37B |
- Stock Market
- Equities
- VKTX Stock
- News Viking Therapeutics, Inc.
- Viking Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023